Clinical Trial Update: Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating fulvestrant or capecitabine in combination with pyrotinib for HR+/HER2+ metastatic breast cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Fulvestrant (fulvestrant)
• Pyrotinib (pyrotinib)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Breast Cancer | Phase 3 | Status: RECRUITING